Jain Deepti
Jain Deepti's purchase track record
Jain Deepti has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/10/2024 | TMCI | $113K | +32.2% | +83.6% | +14.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BTIG Maintains Buy on TCMD, Lowers Price Target to $35. BTIG kept its rating on Tactile Systems Technology while reducing its price target to $35. The new target sits below the analysts' average target of $39 and is near the stock's recent 52‑week high of $37.77. The adjustment may reflect BTIG's view on the company's near‑term outlook.
Transaction History
| TMCI | ▲ Buy | Grant | 30,000 | $0 | 5/19/2026 | View on chart |
| TMCI | ▲ Buy | Grant | 23,917 | $0 | 5/20/2025 | View on chart |
| TMCI | ▲ Buy | Grant | 15,091 | $0 | 5/21/2024 | View on chart |
| TMCI | ▲ Buy | Open Market | 25,000 | $113K | 5/10/2024 | View on chart |
| TMCI | ▲ Buy | Grant | 2,753 | $0 | 5/23/2023 | View on chart |
| TMCI | ▲ Buy | Grant | 1,187 | $0 | 5/17/2022 | View on chart |
| TMCI | ▲ Buy | Grant | 2,295 | $0 | 5/17/2022 | View on chart |
| TCMD | ▲ Buy | Grant | 12,103 | $0 | 5/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.